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Background
The available shunt-systems for the treatment of hydro-
cephalus are exclusively based on simple mechanical prin-
ciples. In comparison to pacemakers or other
sophisticated medical devices, shunt-technology is said to
be "old-fashioned" and the introduction of electronic
intelligent systems should be a second remarkable break-
through after the introduction of the first shunts in the
beginning of the fifties. The decisive question is how far
an electronically controlled device can present new possi-
bilities for the treatment without a significant increase of
new risks. Which concept promises significant improve-
ments?
Materials and methods
All available shunt-systems operate depending on the
pressure difference between the ventricular system and the
abdominal cavity or the atrium of the heart. The used
mechanical principles react to changes of this differential
pressure. The goal is to re-establish physiological pressure
values in the ventricular system of the patient. The obvi-
ous solution to control the intra-ventricular pressure
(IVP) electronically is the opening and closing of the
device depending on the actual measured IVP. But this
simple approach leads to severe unsolved technical prob-
lems like long-term drift and general accuracy. It is a mat-
ter of controversy whether a shunt-system should re-
establish a certain IVP, a certain ventricular size or possi-
bly a certain condition of the brain tissue. However, the
main purpose of drainage is the withdrawal of CSF from
the ventricular system. The amount might depend on
changing individual conditions or on age, on the height of
the patient or on the kind of hydrocephalus. The introduc-
tion of an electronically controlled programmable switch
presents new perspectives for the diagnosis, the general
understanding and the therapy of hydrocephalus. The
switch works without a pressure transducer. The device is
programmed by a physician, who determines at what time
during the day or the night the shunt without a valve is
open or closed. The shunt can be closed at any time non-
invasively or it can be programmed to be always open.
The telemetric programming allows any kind of individ-
ual adaptation. Because a battery is needed, the size of the
device has to be similar to pacemakers. Therefore, it is rec-
ommended to implant the switch in the chest of the
patient.
Results and conclusion
The concept of an electronically controlled switch broad-
ens the possibilities of the treatment of hydrocephalus.
This clear advantage might be counterbalanced by the
drawbacks like the big housing needed or the new risks
introduced by the electronic components. The first
implantations of the new device are scheduled to be per-
formed in the beginning of 2006. If the clinical results
confirm the benefits of the concept the electronic switch
will be an option especially for adult patients with NPH.
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